These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35585214)

  • 1. Enhancing Atorvastatin In Vivo Oral Bioavailability in the Presence of Inflammatory Bowel Disease and Irritable Bowel Syndrome Using Supercritical Fluid Technology Guided by wbPBPK Modeling in Rat and Human.
    Alsmadi MM; Al-Daoud NM; Obaidat RM; Abu-Farsakh NA
    AAPS PharmSciTech; 2022 May; 23(5):148. PubMed ID: 35585214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling.
    Alsmadi MM; Abudaqqa AA; Idkaidek N; Qinna NA; Al-Ghazawi A
    AAPS PharmSciTech; 2024 Apr; 25(4):86. PubMed ID: 38605192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation of Gelucire®-Based Solid Dispersions of Atorvastatin Calcium: In Vitro Dissolution and In Vivo Bioavailability Study.
    Aldosari BN; Almurshedi AS; Alfagih IM; AlQuadeib BT; Altamimi MA; Imam SS; Hussain A; Alqahtani F; Elzayat E; Alshehri S
    AAPS PharmSciTech; 2021 May; 22(5):161. PubMed ID: 34031791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and optimization of a self-microemulsifying drug delivery system for atorvastatin calcium by using D-optimal mixture design.
    Yeom DW; Song YS; Kim SR; Lee SG; Kang MH; Lee S; Choi YW
    Int J Nanomedicine; 2015; 10():3865-77. PubMed ID: 26089663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The In Vitro, In Vivo, and PBPK Evaluation of a Novel Lung-Targeted Cardiac-Safe Hydroxychloroquine Inhalation Aerogel.
    Alsmadi MM; Jaradat MM; Obaidat RM; Alnaief M; Tayyem R; Idkaidek N
    AAPS PharmSciTech; 2023 Aug; 24(6):172. PubMed ID: 37566183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D Supplementation and Mental Health in Inflammatory Bowel Diseases and Irritable Bowel Syndrome Patients: A Systematic Review.
    Głąbska D; Kołota A; Lachowicz K; Skolmowska D; Stachoń M; Guzek D
    Nutrients; 2021 Oct; 13(10):. PubMed ID: 34684663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of geographic distributions of Irritable Bowel Syndrome with Inflammatory Bowel Disease fail to support common evolutionary roots: Irritable Bowel Syndrome and Inflammatory Bowel Diseases are not related by evolution.
    Szilagyi A; Xue X
    Med Hypotheses; 2018 Jan; 110():31-37. PubMed ID: 29317064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of a solidified micelle formulation for enhanced oral bioavailability of atorvastatin calcium using statistical experimental design.
    Goo YT; Won YH; Hong SH; Choi JY; Sin GH; Kim CH; Jung HM; Choi YW
    Pharm Dev Technol; 2023 Jun; 28(5):479-491. PubMed ID: 37099663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EHealth: self-management in inflammatory bowel disease and in irritable bowel syndrome using novel constant-care web applications. EHealth by constant-care in IBD and IBS.
    Pedersen N
    Dan Med J; 2015 Dec; 62(12):B5168. PubMed ID: 26621403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism.
    Lau YY; Okochi H; Huang Y; Benet LZ
    Drug Metab Dispos; 2006 Jul; 34(7):1175-81. PubMed ID: 16624870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stigmatization toward irritable bowel syndrome and inflammatory bowel disease in an online cohort.
    Taft TH; Bedell A; Naftaly J; Keefer L
    Neurogastroenterol Motil; 2017 Feb; 29(2):. PubMed ID: 27501483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin calcium inclusion complexation with polysaccharide arabinogalactan and saponin disodium glycyrrhizate for increasing of solubility and bioavailability.
    Kong R; Zhu X; Meteleva ES; Polyakov NE; Khvostov MV; Baev DS; Tolstikova TG; Dushkin AV; Su W
    Drug Deliv Transl Res; 2018 Oct; 8(5):1200-1213. PubMed ID: 30039497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (Poly)phenols in Inflammatory Bowel Disease and Irritable Bowel Syndrome: A Review.
    Hagan M; Hayee BH; Rodriguez-Mateos A
    Molecules; 2021 Mar; 26(7):. PubMed ID: 33805938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of dissolution of atorvastatin through preparation of polymeric solid dispersions using supercritical fluid technology.
    Altaani B; Obaidat R; Malkawi W
    Res Pharm Sci; 2020 Apr; 15(2):123-136. PubMed ID: 32582352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atazanavir-loaded Eudragit RL 100 nanoparticles to improve oral bioavailability: optimization and in vitro/in vivo appraisal.
    Singh G; Pai RS
    Drug Deliv; 2016; 23(2):532-9. PubMed ID: 24963752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease.
    Gracie DJ; Williams CJ; Sood R; Mumtaz S; Bholah MH; Hamlin PJ; Ford AC
    Clin Gastroenterol Hepatol; 2017 Mar; 15(3):376-384.e5. PubMed ID: 27189912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats.
    Ding C; Li Y; Li X; Meng L; Fu R; Wang X; Li Y; Ma Y; Dong Z
    Pharm Biol; 2022 Dec; 60(1):185-194. PubMed ID: 35001796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methane positive small intestinal bacterial overgrowth in inflammatory bowel disease and irritable bowel syndrome: A systematic review and meta-analysis.
    Gandhi A; Shah A; Jones MP; Koloski N; Talley NJ; Morrison M; Holtmann G
    Gut Microbes; 2021; 13(1):1933313. PubMed ID: 34190027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coping strategies and interpersonal support in patients with irritable bowel syndrome and inflammatory bowel disease.
    Jones MP; Wessinger S; Crowell MD
    Clin Gastroenterol Hepatol; 2006 Apr; 4(4):474-81. PubMed ID: 16616353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome.
    Porter CK; Cash BD; Pimentel M; Akinseye A; Riddle MS
    BMC Gastroenterol; 2012 May; 12():55. PubMed ID: 22639930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.